research Ketoconazole in Cutaneous Leishmaniasis
Ketoconazole cured about 70% of cutaneous leishmaniasis cases caused by Leishmania major.
Search
for
Sort by
Research
60-90 / 1000+ results 
research Association of Alopecia Areata with Atopic Dermatitis and Chronic Spontaneous Urticaria
People with alopecia areata often have higher rates of allergies and autoimmune diseases.
research Signal Transducer and Activator of Transcription 5B Deficiency Due to a Novel Missense Mutation in the Coiled-Coil Domain
A boy's growth and immune problems were caused by a new mutation in the STAT5B gene.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research The Effect of Amniotic Fluid on Hair Follicle Growth
Freezing gamma-irradiated amniotic fluid may help hair growth and speed up the growth phase.
research Risk of Autoimmune Diseases in Patients with RASopathies: Systematic Study of Humoral and Cellular Immunity
Patients with RASopathies have a higher risk of autoimmune disorders and should be routinely screened.
research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Nocturnal Eczema: Review of Sleep and Circadian Rhythms in Children with Atopic Dermatitis and Future Research Directions
Children with atopic dermatitis often have sleep problems, affecting their growth and behavior.
research Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options
The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
research A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata
Apremilast was not effective in treating moderate-to-severe alopecia areata.
research New Drugs Under Investigation for the Treatment of Alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Environmental and Cosmetic Factors in Hair Loss and Damage
Environmental and cosmetic factors, including heat, chemicals, and sun exposure, can cause hair loss and damage.
research Various Applications of Tofacitinib and Ruxolitinib in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Bioinformatics Analysis of Genes Associated with Patchy-Type Alopecia Areata: CD2 May Be a New Therapeutic Target
CD2 might be a new treatment target for patchy alopecia areata.
research TCM Medicine and Food Homology in the Management of Post-COVID Disorders
Traditional Chinese medicinal foods may help manage long-term post-COVID symptoms.
research A Pediatric Case of Severe Allergic Conjunctivitis with Underlying Alopecia Areata
Early and proper treatment is crucial for children with allergic conjunctivitis to avoid complications.
research Effects of Parthenolide on Androgenetic Alopecia in Mice and Human Follicle Dermal Papilla Cells
Parthenolide promotes hair growth in mice and may influence pathways related to male pattern baldness.
research Skin - A Vast Organ with Immunological Function (Review)
The skin is a large organ that plays a role in the immune system.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Does Nirmatrelvir/Ritonavir Influence the Immune Response Against SARS-CoV-2 Independently From Rebound?
Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research The JAK/STAT Signaling Pathway: From Bench to Clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata
Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Risk of Autoimmune Diseases in Patients with RASopathies: Systematic Study of Humoral and Cellular Immunity
Patients with RASopathies are at risk for autoimmune disorders and should be routinely screened.
research Effective Treatment of Refractory Alopecia Areata in Pediatric Patients With Oral Abrocitinib
A new drug, abrocitinib, helped a child with severe hair loss regrow hair.
research Proteomics as a Tool to Improve Novel Insights into Skin Diseases: What We Know and Where We Should Be Going
Proteomics combined with other technologies can lead to a better understanding of skin diseases.
research The Opportunities and Challenges Regarding Induced Platelets from Human Pluripotent Stem Cells
Human pluripotent stem cells could be used to make platelets for medical use, but safety, effectiveness, and cost issues need to be resolved.
research JAK Inhibitors in Dermatology: The Promise of a New Drug Class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Frontiers in Alopecia Areata Pathobiology Research
The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.